Reset
Showing 2 of 2 academic articles

EFFICACY AND SAFETY OF INCLISIRAN BY BASELINE BODY MASS INDEX: A POST HOC POOLED ANALYSIS OF THE ORION-9, ORION-10 AND ORION-11 PHASE III RANDOMIZED CONTROLLED TRIALS

Lawrence A Leiter, David G Kallend, Wolfgang Koenig, Ulf Landmesser et al. • American Journal of Preventive Cardiology (2023)

Therapeutic Area: ASCVD/CVD Risk Factors Background: Excessive bodyweight, often associated with dyslipidemia, may affect the pharmacology of drugs. Inclisiran, a small interfering RNA targeting PCSK9 hepatic mRNA, is an effective LDL-C low...

DOAJ Open Access (DOAJ) DOI: 10.1016/j.ajpc.2022.100403